David
Lockhart

There is a moment in every scientist's career when they find the specific, stubborn problem worth a decade of life. For David J. Lockhart, Ph.D., that problem is the airway. Not the liver — where lipid nanoparticles naturally congregate, drawn there by biological gravity like everything else that enters the bloodstream. The lungs. The trachea. The very cells that genetic respiratory diseases have been destroying, quietly and relentlessly, since birth.

Lockhart is President and Chief Scientific Officer of ReCode Therapeutics, the clinical-stage biotech he has been building — under various names, from TranscripTx onward — since 2014. The company's central bet is that a nonviral lipid nanoparticle can carry mRNA or gene-editing cargo into the lungs via inhalation, bypassing the liver entirely, and deliver functional genetic instructions to the cells that cystic fibrosis and primary ciliary dyskinesia have broken. In January 2024, ReCode dosed its first patient in a Phase 1 clinical study for PCD. The field had been waiting for this proof of concept for decades.

The trick, if you can call it that, is a fifth lipid. Standard LNP formulations use four lipid components. ReCode's SORT LNP platform — Selective ORgan Targeting — adds a chemically distinct fifth lipid that redirects the nanoparticle away from hepatocytes and toward whichever organ you want. Lungs. Spleen. The engineering elegance is almost offensive in its simplicity, once someone has figured it out.

Lockhart says this not as a boast but as a statement of the obvious. The field is full of viral vectors — AAV, lentiviral — that require manufacturing complexity, immune responses, and limitations on payload size. The nonviral path through LNPs is cleaner, scalable, and more amenable to repeat dosing. The reason nobody cracked it for the airway is that the airway is hostile. Mucus. Ciliary clearance. A surface that evolved to keep foreign particles out. Getting mRNA past all of that and into the right cells is not a tweak to the standard delivery playbook. It's a rewrite.

Lockhart began his career doing something that barely existed yet: gene expression profiling using DNA microarrays at Affymetrix, one of the companies that commercialized the technology in the 1990s. Before "genomics" was a household word in biotech, he was building the instruments that made large-scale gene expression analysis possible. The leap from Stanford chemistry to MIT biology to genomics instrumentation is the kind of cross-disciplinary trajectory that looks obvious in retrospect and audacious in real time.

From Affymetrix he moved to the Novartis Research Foundation's Genomics Institute, where he served as Director of Genomics. Then came the entrepreneur chapter: in 2001, he co-founded Ambit Biosciences as President and CSO, focused on kinase profiling technology and small-molecule kinase inhibitors. Kinase inhibitors are now a dominant drug class in oncology. Ambit was early. That pattern — arriving before the wave, building the infrastructure, and then letting the field catch up — is a consistent thread.

From 2006 to 2013, Lockhart was CSO at Amicus Therapeutics, where he led the science that moved multiple rare disease programs from the bench into clinical trials. Amicus focused on pharmacological chaperones and enzyme replacement therapies for lysosomal storage diseases. The rare disease framework — small patient populations, high unmet need, mutation-specific patient selection — would carry forward into ReCode's genetic respiratory disease focus.

In 2014, he took the helm at TranscripTx, the company that would eventually become ReCode Therapeutics. For six years he built the science, the team, and the thesis. The 2020 rebranding to ReCode coincided with a broader recognition that mRNA — accelerated into public consciousness by COVID-19 vaccines — could do far more than infectious disease applications. ReCode's bet on inhaled delivery for genetic disease suddenly had a much larger audience.

By 2022, Lockhart had transitioned from CEO to President and CSO — a deliberate shift to let a dedicated operational CEO run the company while he focused on the science. That's a move that takes self-awareness, the kind that comes from years of watching scientists try to be CEOs and CEOs try to be scientists, and recognizing which chair you actually want to sit in.

ReCode's two lead programs target cystic fibrosis and primary ciliary dyskinesia — both genetic diseases of the respiratory epithelium, both with limited or no approved treatments targeting the underlying cause. CF is caused by mutations in the CFTR gene; CFTR modulators like Trikafta address some mutations but leave a substantial patient population behind. PCD, a rarer condition affecting the cilia that clear mucus from the airways, has no approved disease-modifying treatment at all.

The SORT LNP platform, in theory, can deliver any genetic payload — mRNA, gene-editing machinery, or other RNA-based tools — to the airway cells that need correction. The platform agnosticism matters. If you solve the delivery problem once, you can run multiple programs through the same infrastructure. Each new disease is a payload problem, not a delivery problem. That's the business logic underneath the science.

Lockhart has published over 80 peer-reviewed papers across genomics, kinase biology, pharmacological chaperones, and now genetic medicine delivery. His publication record spans the arc of modern molecular biology — from the early genomics era to the current mRNA therapeutics boom. He holds more than 40 U.S. patents, a number that speaks to a career spent not just observing the frontier but staking claims on it.

The January 2024 dosing of the first PCD patient was not a press release moment for Lockhart — it was the clinical validation of a decade-long conviction. The SORT LNP had gone from a scientific concept to a formulated inhaled therapy now inside a human being with a genetic disease. Whatever the Phase 1 readout shows, the platform has cleared the first real bar: it got into the clinic.

ReCode's $345M war chest — including a $260M Series B that closed in 2022 and a $50M extension in September 2023 — gives Lockhart the runway to see both programs through early clinical stages without the kind of desperate pivoting that can derail early-stage biotechs. The company is not a startup in any conventional sense anymore. It's a clinical-stage company with a platform, pipeline, and a scientist who has spent a quarter century building toward exactly this problem.